<DOC>
	<DOC>NCT01773993</DOC>
	<brief_summary>To collect the efficacy and safety information of Pregabalin on Fibromyalgia patients related to their appropriate use in daily practice.</brief_summary>
	<brief_title>Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first pregabalin should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Clinical diagnosis of Fibromyalgia Pregabalin naive patient Clinical diagnosis of neuropathic pain</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Lyrica</keyword>
	<keyword>pregabalin</keyword>
	<keyword>Good post marketing practice</keyword>
	<keyword>Post Marketing Surveillance</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
	<keyword>Fibromyalgia</keyword>
</DOC>